Uremic toxins and peritoneal dialysis

被引:42
作者
Lameire, N [1 ]
Vanholder, R [1 ]
De Smet, R [1 ]
机构
[1] State Univ Ghent Hosp, Dept Med, Div Renal, B-9000 Ghent, Belgium
关键词
end-stage renal disease; residual renal function; hyper-homocysteinemia; p-Cresol; beta(2)-microglubulin; advanced glycation end products; advanced oxidation protein product;
D O I
10.1046/j.1523-1755.2001.59780292.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Uremic toxicity is related in part to the accumulation of toxic substances, the nature of which has only partly been characterized. Because of the use of a highly permeable membrane and better preservation of the residual renal function, it could be anticipated that some of these uremic toxins are more efficiently cleared across the peritoneal membrane, and that the plasma and tissue levels of these compounds are lower than in hemodialysis patients. This article analyzes the generation and removal of several uremic toxins in peritoneal dialysis patients. The following uremic toxins are discussed: beta (2)-microglobulin, advanced glycation end products, advanced oxidation protein products, granulocyte inhibitory proteins, p-Cresol, and hyperhomocysteinemia. Some recent studies are reviewed suggesting that uremic toxins are involved in the progression of renal failure and are at least partially removed by peritoneal dialysis. We conclude that, although the plasma levels of some of these compounds are lower in peritoneal dialysis versus hemodialysis patients, it does not mean that the peritoneal dialysis patient is "better" protected against the numerous disturbances caused by these toxins.
引用
收藏
页码:S292 / S297
页数:6
相关论文
共 47 条
  • [1] BERGSTROM J, 1997, UREMIC TOXICITY NUTR, P97
  • [2] Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes
    Bostom, AG
    Lathrop, L
    [J]. KIDNEY INTERNATIONAL, 1997, 52 (01) : 10 - 20
  • [3] The impact of an amino acid-based peritoneal dialysis fluid on plasma total homocysteine levels, lipid profile and body fat mass
    Brulez, HFH
    van Guldener, C
    Donker, AJM
    ter Wee, PM
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (01) : 154 - 159
  • [4] Catizone L, 1995, ADV PERIT D, V11, P213
  • [5] Cohen G, 1998, J AM SOC NEPHROL, V9, P451
  • [6] Cohen G, 1997, MINER ELECTROL METAB, V23, P210
  • [7] Dawnay A, 1998, CELL MOL BIOL, V44, P1081
  • [8] Dawnay ABSJ, 1997, PERITON DIALYSIS INT, V17, P52
  • [9] DeSmet R, 1997, KIDNEY INT, V52, pS8
  • [10] DIRAIMONDO CR, 1988, PERITON DIALYSIS INT, V8, P43